"We are thrilled to have Howie join our Board of Directors during this exciting time as our discoveries advance closer to IND filings," said Andrew Radin, CEO of twoXAR. "He has been a trusted advisor to the company since its inception and brings a wealth of experience in leading and advising pharmaceutical companies. We are grateful to have his expertise and insight as we continue to expand our research programs and partnerships."
Rosen brings more than 25 years of experience in the pharmaceutical and biotechnology industries to the twoXAR Board. His previous experience includes leadership roles at Kala Pharmaceuticals, Gilead Sciences, and ALZA Corporation (a Johnson & Johnson company). Rosen received an MBA from Stanford University Graduate School of Business, an MS in Chemical Engineering from MIT.
"I could not be more excited to join the Board and work alongside some of the most talented individuals in the industry," said Rosen. "While I have had the opportunity to witness the progress twoXAR has made rapidly advancing therapies through discovery and early development, I now look forward to helping the company realize its vision of bringing these therapies to patients in need."